title: Agents in development for the treatment of diabetic nephropathy.
abstract: BACKGROUND
  Nephropathy is a major cause of morbidity and mortality in diabetic patients. Current treatments include optimization of glycemic and blood pressure control, but more innovative strategies are needed for the prevention and treatment of diabetic nephropathy.
  
  
  OBJECTIVE
  To review emerging therapies for diabetic nephropathy.
  
  
  METHODS
  This paper discusses the molecular mechanisms of diabetic nephropathy and the potential therapeutic interventions.
  
  
  CONCLUSIONS
  New therapies, including those targeting the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS) generation, are likely to feature in future treatment regimens. Other approaches that at this stage do not appear to be progressing include the glycosaminoglycan sulodexide and the protein kinase C-beta (PKC-beta) inhibitor, ruboxistaurin.
authors.affiliation: Albert Einstein Juvenile Diabetes Research Foundation Centre for Diabetes Complications, Diabetes and Metabolism Division, Baker Medical Research Institute, PO Box 6492, St Kilda Road Central, Melbourne, Victoria, 8008, Australia.
authors.forename: Su-Yen
authors.initials: SY
authors.lastname: Goh
authors.forename: Mariusz
authors.initials: M
authors.lastname: Jasik
authors.forename: Mark E
authors.initials: ME
authors.lastname: Cooper